Related Experiment Video

Updated: Jun 10, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.1K

Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs

Marco Zuin1,2, Alberto Corsini3, Chiara Dalla Valle4

  • 1Department of Translational Medicine, University of Ferrara, Via Luigi Borsari 46, Ferrara 44121, Italy.

European Heart Journal. Cardiovascular Pharmacotherapy
|October 15, 2024
PubMed

Insights

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) show promise in reducing cardiovascular events and may benefit patients with venous thromboembolism (VTE). Further research is needed to confirm their efficacy and safety alongside anticoagulation.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) effectively lower LDL cholesterol.
  • Emerging data suggest PCSK9i may reduce venous thromboembolism (VTE) risk, particularly with long-term use.
  • Current evidence lacks robust randomized controlled data on PCSK9i efficacy and safety in VTE management.

Purpose of the Study:

  • To critically evaluate the existing evidence for PCSK9i in VTE risk reduction.
  • To identify unmet clinical and research needs regarding PCSK9i as adjunctive VTE therapy.
  • To propose strategies for addressing current knowledge gaps in PCSK9i use for VTE.

Main Methods:

  • Literature review and critical appraisal of available randomized controlled trials (RCTs) and preliminary evidence.
  • Analysis of potential benefits and risks of PCSK9i in the context of standard anticoagulation.
  • Identification of gaps in clinical data and research methodologies.

Main Results:

  • Preliminary RCT data indicate potential long-term benefits of PCSK9i in reducing VTE risk.
  • Significant risk reduction observed beyond the first year of PCSK9i treatment.
  • Lack of comprehensive randomized data on combined efficacy and safety with anticoagulants.

Conclusions:

  • PCSK9i represent a potential adjunctive therapy for VTE risk reduction, warranting further investigation.
  • Randomized controlled trials are essential to establish definitive efficacy and safety profiles.
  • Future research should focus on long-term outcomes and optimal integration with anticoagulation strategies.
Keywords:
PCSK9 inhibitorsPreventionVenous Thromboembolism thromboembolism

More Related Videos

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

578
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.7K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
3
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
480
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
3
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
3